CSF1 and cancer: Following determination of superior sensitivity and specificity of M-CSF over traditional markers (e.g., CA-125, CA-19-9), it was recommended that this cytokine was potentially a suitable marker that fulfilled important criteria for diagnosis of several cancers such as ovarian and pancreatic cancer; and potentially ready for validation and technology development (electronic devices) to be used in clinical settings [48,57].